Alvotech to Present at Goldman Sachs' Annual Global Healthcare Conference in Miami.

Alvotech, a biotechnology firm, will participate in Goldman Sachs' annual healthcare conference in Miami from June 9-11. The company's CEO, Dr. Balaji Prasad, will present on the firm's recent developments on June 11 at 12:00 PM. The conference will be live-streamed and available on the company's website for 90 days after the conference. Alvotech is focused on developing and manufacturing high-quality biologics for patients worldwide, with partnerships with major pharmaceutical companies across the globe.

Alvotech, a leading biotechnology firm, will participate in Goldman Sachs' annual healthcare conference in Miami from June 9-11. The company's CEO, Dr. Balaji Prasad, will present on the firm's recent developments on June 11 at 12:00 PM. The conference will be live-streamed and available on the company's website for 90 days after the event. Alvotech is focused on developing and manufacturing high-quality biologics for patients worldwide, with partnerships with major pharmaceutical companies across the globe.

The presentation is expected to highlight Alvotech's recent collaboration with Dr. Reddy’s Laboratories (RDY) to co-develop and commercialize a biosimilar candidate to Merck’s (MRK) Keytruda (pembrolizumab). Keytruda, a blockbuster cancer drug, generated sales worth $29.5 billion in 2024 and has been a significant revenue driver for Merck. The biosimilar candidate aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028 [1].

Under the terms of the agreement, both companies will jointly share all costs for developing and manufacturing the biosimilar candidate. Each company will hold the right to commercialize the product globally upon successful development. This collaboration is expected to significantly enhance Dr. Reddy’s biosimilar portfolio across emerging markets and expand Alvotech's pipeline into global markets [2].

The partnership marks a strategic boost to Dr. Reddy’s oncology portfolio and expands Alvotech's biosimilar pipeline as Keytruda patents near expiry. The tie-up comes amid growing global demand for cost-effective biologic alternatives in cancer care, especially in immuno-oncology, where Keytruda remains a dominant therapy [3].

References:
[1] https://finviz.com/news/74522/rdy-alvo-ink-collaboration-deal-for-mercks-keytruda-biosimilar
[2] https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/dr-reddys-alvotech-to-co-develop-keytruda-biosimilar/articleshow/121654882.cms?from=mdr
[3] https://www.business-standard.com/companies/news/dr-reddys-alvotech-partner-on-keytruda-biosimilar-development-125060501002_1.html